-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on IRulya Therapeutics, Raises Price Target to $86

Benzinga·11/16/2026 14:00:23
Listen to the news
Citizens analyst Jonathan Wolleben maintains IRulya Therapeutics (NASDAQ:IRLA) with a Market Outperform and raises the price target from $77 to $86.